MA55021A - 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression - Google Patents

5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Info

Publication number
MA55021A
MA55021A MA055021A MA55021A MA55021A MA 55021 A MA55021 A MA 55021A MA 055021 A MA055021 A MA 055021A MA 55021 A MA55021 A MA 55021A MA 55021 A MA55021 A MA 55021A
Authority
MA
Morocco
Prior art keywords
dimethyltryptamine
dmt
meo
depression
methoxy
Prior art date
Application number
MA055021A
Other languages
English (en)
Other versions
MA55021B1 (fr
Inventor
Theis Terwey
Original Assignee
Gh Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gh Res Limited filed Critical Gh Res Limited
Publication of MA55021A publication Critical patent/MA55021A/fr
Publication of MA55021B1 publication Critical patent/MA55021B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA55021A 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure MA55021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22
PCT/EP2020/054803 WO2020169850A1 (fr) 2019-02-22 2020-02-24 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Publications (2)

Publication Number Publication Date
MA55021A true MA55021A (fr) 2021-12-29
MA55021B1 MA55021B1 (fr) 2024-05-31

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55021A MA55021B1 (fr) 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure

Country Status (32)

Country Link
US (2) US20220071958A1 (fr)
EP (3) EP4349407B1 (fr)
JP (2) JP7598326B2 (fr)
KR (1) KR20210154966A (fr)
CN (1) CN114555078A (fr)
AU (2) AU2020225410B2 (fr)
BR (1) BR112021016153A2 (fr)
CA (1) CA3130406A1 (fr)
CL (1) CL2021002174A1 (fr)
CO (1) CO2021010882A2 (fr)
CR (1) CR20210437A (fr)
DK (2) DK3927337T3 (fr)
DO (1) DOP2021000176A (fr)
EA (1) EA202192318A1 (fr)
EC (1) ECSP21060868A (fr)
ES (2) ES2984438T3 (fr)
FI (2) FI3927337T3 (fr)
HR (2) HRP20250590T1 (fr)
HU (2) HUE066828T2 (fr)
IL (1) IL285537A (fr)
LT (2) LT3927337T (fr)
MA (1) MA55021B1 (fr)
MD (1) MD3927337T2 (fr)
MX (2) MX2021009941A (fr)
NI (1) NI202100080A (fr)
PE (1) PE20220015A1 (fr)
PL (2) PL4349407T3 (fr)
PT (2) PT4349407T (fr)
RS (2) RS65706B1 (fr)
SI (2) SI4349407T1 (fr)
SM (1) SMT202400154T1 (fr)
WO (1) WO2020169850A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4349407T1 (sl) 2019-02-22 2025-06-30 GH Research Ireland Limited 5-metoksi-n,n-dimetiltriptamin (5-meo-dmt) za zdravljenje velike depresivne motnje
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (fr) * 2019-06-19 2020-12-23 GH Research Limited Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant
NZ788543A (en) 2019-11-07 2022-10-28 Small Pharma Ltd Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
EP3868364A1 (fr) 2020-02-24 2021-08-25 GH Research Limited Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine
US11759452B2 (en) 2020-05-08 2023-09-19 Psilera Inc. Compositions of matter and pharmaceutical compositions
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2021250435A1 (fr) 2020-06-12 2021-12-16 Beckley Psytech Limited Composition pharmaceutique comprenant de la 5-méthoxy-n, n-diméthyltryptamine
CN116056705A (zh) * 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
KR20230053611A (ko) 2020-08-18 2023-04-21 사이빈 아이알엘 리미티드 펜에틸아민 유도체, 조성물, 및 사용 방법
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20230355583A1 (en) * 2020-10-02 2023-11-09 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (fr) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Méthode de traitement par alcaloïdes tryptamines
EP4255421A1 (fr) * 2020-12-01 2023-10-11 Small Pharma Ltd Formulations inhalables
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (fr) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Protocole psychedelique pour systemes et methodes informatiques
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CN117320711A (zh) 2021-04-26 2023-12-29 阿泰治疗公司 新型n,n-二甲基色胺组合物和方法
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
IL308068A (en) * 2021-05-03 2023-12-01 Mind Medicine Inc A method for dose titration of psychedelics
US20240246911A1 (en) * 2021-05-05 2024-07-25 Gilgamesh Pharmaceuticals Novel tryptamines and methods of treating mood disorders
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (fr) 2021-06-09 2022-12-15 ATAI Life Sciences AG Nouveaux promédicaments et conjugués de diméthyltryptamine
EP4387624A4 (fr) 2021-08-19 2025-07-30 Mind Medicine Inc Formulations à libération immédiate de diéthylamide de l'acide d-lysergique pour des applications thérapeutiques
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
IL312859A (en) * 2021-11-18 2024-07-01 Cybin Uk Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4486448A1 (fr) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
KR20250005178A (ko) 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 수면 장애의 치료에 사용하기 위한 5-meo-dmt
WO2023186834A1 (fr) 2022-03-27 2023-10-05 GH Research Ireland Limited Sel de bromhydrate cristallin de 5-meo-dmt
WO2023186816A1 (fr) 2022-03-27 2023-10-05 GH Research Ireland Limited Traitement de l'anxiété
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024160391A1 (fr) 2023-01-30 2024-08-08 GH Research Ireland Limited Traitement de troubles mentaux
EP4658265A1 (fr) 2023-01-30 2025-12-10 GH Research Ireland Limited 5-méthoxy-n,n-diméthyltryptamine pour le traitement de la dépression post-partum
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (fr) * 2023-06-08 2024-12-12 Cybin Irl Limited Traitements d'animaux de compagnie
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025068714A1 (fr) * 2023-09-28 2025-04-03 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
AU2024367931A1 (en) 2023-10-23 2026-02-26 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
WO2025111597A1 (fr) * 2023-11-22 2025-05-30 Gilgamesh Pharmaceuticals, Inc. Traitement de patients atteints de troubles de l'humeur à l'aide de n-éthyl-2-(5-fluoro-1h-indol-3-yl)-n-méthyléthan-1-amine ou d'un sel pharmaceutiquement acceptable de celle-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
EP1884254B8 (fr) 2006-08-01 2011-02-23 Stobi GmbH & Co. KG Ballon à valve pour inhalateurs
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
SI4349407T1 (sl) 2019-02-22 2025-06-30 GH Research Ireland Limited 5-metoksi-n,n-dimetiltriptamin (5-meo-dmt) za zdravljenje velike depresivne motnje

Also Published As

Publication number Publication date
EP4349407B1 (fr) 2025-04-09
EP4353314A3 (fr) 2024-07-03
JP2022521337A (ja) 2022-04-06
HUE066828T2 (hu) 2024-09-28
DK3927337T3 (da) 2024-04-22
EP4353314A2 (fr) 2024-04-17
SI3927337T1 (sl) 2024-07-31
DK4349407T3 (da) 2025-05-26
MX2025002567A (es) 2025-04-02
NI202100080A (es) 2021-12-06
US20220071958A1 (en) 2022-03-10
SMT202400154T1 (it) 2024-07-09
SI4349407T1 (sl) 2025-06-30
PL4349407T3 (pl) 2025-07-21
EP3927337B1 (fr) 2024-02-14
PL3927337T3 (pl) 2024-07-29
KR20210154966A (ko) 2021-12-21
BR112021016153A2 (pt) 2021-10-05
EP4349407A3 (fr) 2024-07-03
CR20210437A (es) 2021-11-02
RS65706B1 (sr) 2024-08-30
MX2021009941A (es) 2021-12-10
FI4349407T3 (fi) 2025-06-02
CO2021010882A2 (es) 2022-01-17
JP2025029035A (ja) 2025-03-05
JP7598326B2 (ja) 2024-12-11
HUE071841T2 (hu) 2025-09-28
ECSP21060868A (es) 2021-11-30
CN114555078A (zh) 2022-05-27
FI3927337T3 (fi) 2024-05-08
US20240307350A1 (en) 2024-09-19
EP4349407A2 (fr) 2024-04-10
PT3927337T (pt) 2024-05-17
EP3927337A1 (fr) 2021-12-29
LT4349407T (lt) 2025-07-10
HRP20240532T1 (hr) 2024-07-19
CL2021002174A1 (es) 2022-01-28
EA202192318A1 (ru) 2021-12-21
EP3927337B8 (fr) 2024-03-20
WO2020169850A1 (fr) 2020-08-27
AU2020225410A1 (en) 2021-08-19
IL285537A (en) 2021-09-30
HRP20250590T1 (hr) 2025-07-04
LT3927337T (lt) 2024-07-10
MD3927337T2 (ro) 2024-08-31
CA3130406A1 (fr) 2020-08-27
PT4349407T (pt) 2025-06-04
RS66912B1 (sr) 2025-07-31
MA55021B1 (fr) 2024-05-31
DOP2021000176A (es) 2021-11-21
AU2020225410B2 (en) 2025-10-30
PE20220015A1 (es) 2022-01-11
AU2026200720A1 (en) 2026-02-19
ES2984438T3 (es) 2024-10-29
ES3031965T3 (en) 2025-07-14

Similar Documents

Publication Publication Date Title
MA55021A (fr) 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
MA47719A (fr) Esketamine pour le traitement de la dépression
DK3927338T3 (da) Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
EP3908270A4 (fr) Combinaison de dextrométhorphane et de bupropion pour le traitement de la dépression
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3946357A4 (fr) Formulations topiques pour le traitement de neuropathies périphériques
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
EP3749064A4 (fr) Machine de traitement au plasma
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3285795A4 (fr) Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3634463A4 (fr) Protocole amélioré pour le traitement de la néphropathie lupique
EP3903725A4 (fr) Structure de jonction pour traitement
EP3813738A4 (fr) Revêtement nanofibreux pro-régénérateur pro-réparateur pour implants médicaux
EP3472320A4 (fr) Dysferline tronquée pour le traitement de la dysferlinopathie
MA55531A (fr) Procédés pour le traitement de béta-thalassémie
EP3953485A4 (fr) Modulation de htra1 pour le traitement de la dmla
MA42419A (fr) Méthode de traitement de l'encéphalopathie hépatique
EP3960307A4 (fr) Liquide de traitement
MA48791A (fr) Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies
EP3324993A4 (fr) Composition pour le traitement du vrs